The Column Group

In November 2017, Exonics secured a $40 million Series A financing from The Column Group (TCG), a San Francisco-based venture capital firm. TCG is a science-driven venture capital firm that partners with exceptional scientific founders, entrepreneurs, executives, and investment organizations with a shared vision for building the next generation of drug discovery and development companies. TCG invests in innovative drug discovery companies with the potential to become leaders in their respective fields.

CureDuchenne Ventures

Exonics’ seed funding was provided by CureDuchenne Ventures (CDV), an organization committed to facilitating the development of drugs to treat Duchenne. CureDuchenne Ventures was formed by CureDuchenne, a national nonprofit that has funded nine research projects that have advanced to human clinical trials. CDV has close ties with the Duchenne community, which includes patients, families, physicians and scientists in academia and industry. These relationships and CDV’s deep knowledge of Duchenne and all therapeutic approaches for the disease were especially important.